Intra-Cellular Therapies: Q4 Earnings Beat Revenue Expectations Despite Loss

Intra-Cellular Therapies Inc. (ITCI) reported its fourth-quarter and full-year 2025 financial results, providing insights into the company's performance and growth potential. The biopharmaceutical company, focused on developing novel treatments for psychiatric and neurological disorders, posted a loss of $85.7 million in the fourth quarter, with a loss per share of $1.05. Despite the loss, the company's revenue of $25.7 million beat Street forecasts, indicating strong market demand for its products.